Rani Therapeutics Holdings, Inc.
RANIHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Rani Therapeutics Holdings, Inc. focuses on Biotechnology services and products. Rani Therapeutics Holdings, Inc. With a market capitalization of $85.1M, it sits in micro-cap territory. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.
Market Cap
$85.1M
Beta
0.71
P/E (TTM)
—
P/E (Fwd)
-3.19
EPS (TTM)
$-0.15
EPS (Fwd)
$-0.19
ROE
-172.2%
ROA
-53.0%
Cash
$53.4M
Total Debt
$3.5M
Free CF
-$8.9M
52W Change
-66.0%
Annual Financials
Cash vs Debt
Where RANI stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, RANI finished 23.53% below its 150-day moving average ($0.85) and 32.99% below its 200-day moving average ($0.97). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RANI overbought or oversold?
At the October 20, 2026 close, RANI's RSI(14) was 28.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Rani Therapeutics Holdings, Inc. holds $53.4M in cash against $3.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$8.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -172.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, RANI has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing RANI.